Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Hamster, Human, Mouse, Non-human primate, Rat|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Synthetic peptide corresponding to amino-terminal residues of human beta-Actin, conjugated to KLH.|
|Contains||0.03% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1/200 - 1/400|
|Immunofluorescence (IF)||1/200 - 1/1000|
|Western Blot (WB)||1/500 - 1/2000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-15452 targets beta-Actin in FACS, IF, and WB applications and shows reactivity with Hamster, Human, mouse, Non-human primate, and Rat samples.
The MA5-15452 immunogen is synthetic peptide corresponding to amino-terminal residues of human beta-Actin, conjugated to KLH.
MA5-15452 detects beta-Actin which has a predicted molecular weight of approximately 42kDa.
This gene encodes one of six different actin proteins. Actins are highly conserved proteins that are involved in cell motility, structure, and integrity. This actin is a major constituent of the contractile apparatus and one of the two nonmuscle cytoskeletal actins.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins.
MA5-15452 was used in western blot to characterize 3D-cultured prostate cancer cells' drug response and expression of drug-action associated proteins and the influence of matrices
|Edmondson R,Adcock AF,Yang L||PloS one (11:null)||2016|
An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
MA5-15452 was used in immunohistochemistry - paraffin section to discuss the use of antibody-drug conjugates to deliver cytotoxic agents to tumors
|Asundi J,Crocker L,Tremayne J,Chang P,Sakanaka C,Tanguay J,Spencer S,Chalasani S,Luis E,Gascoigne K,Desai R,Raja R,Friedman BA,Haverty PM,Polakis P,Firestein R||Clinical cancer research : an official journal of the American Association for Cancer Research (21:3252)||2015|
ACTB; actin, beta; Actin, cytoplasmic 1; Atcb; beta cytoskeletal actin; Beta-actin; cytoplasmic beta-actin; PS1TP5-binding protein 1; PS1TP5BP1
ACTB; Actx; beta-actin; BRWS1; E430023M04Rik; PS1TP5BP1